account_balance
Investment manager · 13F filer · SEC CIK 2088557
Defilade Capital Management, L.P.
Reported value$747Mas of Jun 30, 2026
Positions39 20 new, 12 sold out
Top 10 weight46.5%LLY alone is 6%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
LLYEli Lilly & Co
6.3%Added +89%
PFEPfizer Inc
5.7%Added +21%
VEEVVeeva Sys Inc
5.6%New
BMRNBiomarin Pharmaceutical Inc
5.2%New
PTCTPTC Therapeutics Inc
4.7%Added +15%
BAXBaxter Intl Inc
4.2%New
INSMInsmed Inc
4.0%Added +45%
ZBHZimmer Biomet Holdings Inc
3.7%Trimmed −45%
PODDInsulet Corp
3.6%New
TMOThermo Fisher Scientific Inc
3.5%New
ABTAbbott Laboratories
3.5%New
ASNDAscendis Pharma A/s
3.4%New
LLY6.3%PFE5.7%VEEV5.6%
BMRNBiomarin Pharmaceutical Inc
5.2%New
PTCTPTC Therapeutics Inc
4.7%Added +15%
BAXBaxter Intl Inc
4.2%New
INSM4.0%ZBH3.7%PODD3.6%TMO3.5%ABT3.5%ASND3.4%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
LLY Eli Lilly & Co 6.3% Added +89%PFE Pfizer Inc 5.7% Added +21%VEEV Veeva Sys Inc 5.6% NewBMRN Biomarin Pharmaceutical Inc 5.2% NewPTCT PTC Therapeutics Inc 4.7% Added +15%BAX Baxter Intl Inc 4.2% NewINSM Insmed Inc 4.0% Added +45%ZBH Zimmer Biomet Holdings Inc 3.7% Trimmed −45%PODD Insulet Corp 3.6% NewTMO Thermo Fisher Scientific Inc 3.5% NewABT Abbott Laboratories 3.5% NewASND Ascendis Pharma A/s 3.4% New
What changed